2020 © American Society of Health-System Pharmacists
Elaine K. Snow, B.S. Pharm.
1-58528-611-7 / 978-1-58528-611-9
Pharmacy/Pharmacology, Drug Information, Neurology, Ophthalmology, Point of Care, Public Health
2020 Updates Include:
- • Management of opiate use disorder
- • Multimodal pain management strategies for non-opiate analgesic agents and opiate-sparing drugs
- • Current best practices for management of pain and sedation in critically ill patients such as the concept of analgosedation and comparisons of various sedative agents used for ICU sedation
- • Newly published information on breakthrough oncology drugs approved as part of the FDA’s accelerated approval program
- • Updating of pharmacogenomic considerations related to dosage adjustments (e.g., tamoxifen) or risk of sensitivity reactions (e.g., allopurinol, phenytoin or fosphenytoin)
- • Expanded information on non-oncology off-label uses (e.g., mycophenolate in treating scleroderma; ketamine use in treatment-resistant depression)
- • Addition of new therapies for the treatment of seizure disorders, including status epilepticus and intractable childhood epilepsy syndromes
- • Use of Calcitonin Gene-Related Peptide (CGRP) antagonists in the preventive treatment of migraines
- • Important changes in management of diabetes, including effects of SGLT2 inhibitors and GLP-1 agonists on cardiovascular risk reduction and beneficial effects on renal function
Special Feature: A discussion of recent evidence questioning aspirin’s role in primary prevention of cardiovascular events in most adults, including the American College of Cardiology and American Heart Association’s positions.
This title updates: Monthly
Doody's Core Titles (DCT)
Essential Purchase Title (EPT)
Specialty Score: 2.87 Health Sciences - Pharmacology/Pharmacy
Quotes, Reviews or Testimonials
"This reference is widely used and trusted for its established record in refuting unfounded efficacy claims, its rigorous science-based editorial process, and its independence from the influence of pharmaceutical manufacturers."
-- Jennifer Colon, PharmD, MS, MBA (Temple University School of Pharmacy) - previous edition
"You cannot be a pharmacist without this book. For clinical pharmacists especially it is the standard..."
-- Miriam Klein, Pharm.D. R.Ph. (Woodhull Medical Center) - previous edition
“AHFS Drug Information is by far the most comprehensive and informative drug reference that I use. It offers much more in-depth information and post-marketing [after FDA approval] analysis on drugs.”
-- Jay S. Cohen, M.D., Associate Professor of Family and Preventive Medicine, University of California at San Diego Medical School - previous edition
“There is more in-depth information in AHFS DI, particularly pharmacology and kinetics. At times I especially need the unlabeled uses in AHFS Drug Information to answer questions. Other references don't include as many off-label uses.”
-- Paul Matuschka, Pharm.D., VA Medical Center, Louisville, KY - previous edition
This reference is intended to shape treatment decisions made by practitioners and clinicians and to influence public and private healthcare policies and decisions. It can be used as a valuable and unbiased pharmaceutical reference by clinical students and practitioners.
Table of Contents